BR112021017310A8 - Método para produzir vacina fracionada de ha de influenza - Google Patents

Método para produzir vacina fracionada de ha de influenza

Info

Publication number
BR112021017310A8
BR112021017310A8 BR112021017310A BR112021017310A BR112021017310A8 BR 112021017310 A8 BR112021017310 A8 BR 112021017310A8 BR 112021017310 A BR112021017310 A BR 112021017310A BR 112021017310 A BR112021017310 A BR 112021017310A BR 112021017310 A8 BR112021017310 A8 BR 112021017310A8
Authority
BR
Brazil
Prior art keywords
influenza
vaccine
fractioned
fractionated
stem region
Prior art date
Application number
BR112021017310A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112021017310A2 (en, 2012
Inventor
Takahashi Yoshimasa
Adachi Yu
Ato Manabu
Original Assignee
Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases, Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases
Publication of BR112021017310A2 publication Critical patent/BR112021017310A2/pt
Publication of BR112021017310A8 publication Critical patent/BR112021017310A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR112021017310A 2019-03-04 2020-03-03 Método para produzir vacina fracionada de ha de influenza BR112021017310A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019038662 2019-03-04
PCT/JP2020/008974 WO2020179797A1 (ja) 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (2)

Publication Number Publication Date
BR112021017310A2 BR112021017310A2 (en, 2012) 2021-11-16
BR112021017310A8 true BR112021017310A8 (pt) 2022-12-06

Family

ID=72337458

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017310A BR112021017310A8 (pt) 2019-03-04 2020-03-03 Método para produzir vacina fracionada de ha de influenza

Country Status (14)

Country Link
US (1) US20220152191A1 (en, 2012)
EP (1) EP3936147A4 (en, 2012)
JP (1) JP7545955B2 (en, 2012)
KR (1) KR20210135261A (en, 2012)
CN (1) CN114096273A (en, 2012)
AU (1) AU2020233456A1 (en, 2012)
BR (1) BR112021017310A8 (en, 2012)
CA (1) CA3132578A1 (en, 2012)
EA (1) EA202192398A1 (en, 2012)
IL (1) IL285984A (en, 2012)
MX (1) MX2021010685A (en, 2012)
PH (1) PH12021552094A1 (en, 2012)
SG (1) SG11202109566XA (en, 2012)
WO (1) WO2020179797A1 (en, 2012)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021550175A1 (en) 2018-07-23 2022-07-11 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Composition containing influenza vaccine
CN114929270A (zh) * 2019-11-07 2022-08-19 塞其里斯英国有限公司 用于生产具有减小的颗粒大小的病毒疫苗的组合物和方法
WO2024225404A1 (ja) * 2023-04-26 2024-10-31 国立感染症研究所長が代表する日本国 抗インフルエンザ抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US20230201329A1 (en) * 2006-07-17 2023-06-29 Glaxosmithkline Biologicals Sa Influenza vaccine
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2744354C (en) * 2008-11-25 2018-10-02 Avir Green Hills Biotechnology Research Development Trade Ag Method for production of ph stable enveloped viruses
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗
CN104302317B (zh) * 2012-05-16 2016-07-06 Kj生物科学有限公司 新型和改进的流感疫苗
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
WO2016178811A1 (en) * 2015-05-04 2016-11-10 Epivax, Inc. Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
ES2805724T3 (es) * 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
CN110650729B (zh) * 2017-03-29 2024-08-20 住友制药株式会社 疫苗佐剂制剂
JP7403733B2 (ja) * 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
PH12021550175A1 (en) * 2018-07-23 2022-07-11 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Composition containing influenza vaccine
CA3121613A1 (en) * 2018-12-26 2020-07-02 Sumitomo Dainippon Pharma Co., Ltd. Preparation including vaccine adjuvant
BR112021017074A2 (pt) * 2019-02-28 2021-11-09 Novavax Inc Métodos para prevenir doença ou distúrbio causado(a) por infecção por rsv

Also Published As

Publication number Publication date
BR112021017310A2 (en, 2012) 2021-11-16
IL285984A (en) 2021-10-31
PH12021552094A1 (en) 2022-05-30
AU2020233456A1 (en) 2021-10-07
EP3936147A4 (en) 2022-09-28
WO2020179797A1 (ja) 2020-09-10
MX2021010685A (es) 2021-12-10
US20220152191A1 (en) 2022-05-19
EA202192398A1 (ru) 2021-11-23
JP7545955B2 (ja) 2024-09-05
EP3936147A1 (en) 2022-01-12
JPWO2020179797A1 (en, 2012) 2020-09-10
CN114096273A (zh) 2022-02-25
SG11202109566XA (en) 2021-10-28
CA3132578A1 (en) 2020-09-10
KR20210135261A (ko) 2021-11-12

Similar Documents

Publication Publication Date Title
BR112021017310A8 (pt) Método para produzir vacina fracionada de ha de influenza
CL2021001171A1 (es) Compuestos de anillo fusionado.
MX2022000733A (es) Derivados cannabinoides como compuestos farmaceuticamente activos y metodos de preparacion de los mismos.
PH12020500414A1 (en) Method for producing influenza ha split vaccine
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
BRPI1012082A2 (pt) composição aquosa , método para preparar um composição de igg concentrada a partir de plasma , e, uso da composição.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
CL2019001200A1 (es) Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta.
CO2020001927A2 (es) Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3
BR112019025548A2 (pt) Inibição ou redução do crescimento de plantas por biocimentação
MX2021010060A (es) Produccion de virus en huevos aviares.
BR112019008011A2 (pt) método para controlar uma instalação de energia eólica, instalação de energia eólica, e, parque eólico
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
BR112019005886A2 (pt) tratamento com água de material lipídico
BR112021001188A8 (pt) Composição que contém vacina contra a influenza
MX2022000203A (es) Composiciones de liberacion sostenida de endoxifeno.
UY38895A (es) PROCESO PARA PREPARAR (15a,16a,17ß)-ESTRA-1,3,5(10)-TRIENO-3,15,16,17-TETROL (ESTETROL) E INTERMEDIOS DE DICHO PROCESO
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
BR112022003788A2 (pt) Plantas transformadas e métodos para produzir e usar as mesmas
BR112022008286A2 (pt) Compostos transportadores de hidrogênio
JP2019043937A5 (en, 2012)
BR112019006087A2 (pt) composição de cuidados bucais e método para beneficiar dentes de um indivíduo

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP) ; SUMITOMO PHARMA CO., LTD. (JP)